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Abstract
Deep sequencing is able to generate a complete picture of the retroviral quasi-species in a patient. We demon-
strate that the unprecedented power of deep sequencing in conjunction with computational data analysis has
great potential for clinical diagnostics and basic research. Specifically, we analyzed longitudinal deep sequencing
data from patients in a study with Vicriviroc, a drug that blocks the HIV-1 co-receptor CCR5. Sequences covered
the V3-loop of gp120, known to be the main determinant of co-receptor tropism. First, we evaluated this data with
a computational model for the interpretation of V3-sequences with respect to tropism, and we found complete
agreement with results from phenotypic assays. Thus, the method could be applied in cases where phenotypic
assays fail. Second, computational analysis led to the discovery of a characteristic pattern in the quasi-species that
foreshadows switches of co-receptor tropism. This analysis could help to unravel the mechanism of tropism
switches, and to predict these switches weeks to months before they can be detected by a phenotypic assay.
Findings
Human Immunodeficiency Virus 1 (HIV-1) enters cells
in a complex process involving interactions of viral
envelope protein gp120 with the cellular receptor
CD4 and a co-receptor, typically one of the chemokine
receptors CCR5 or CXCR4 [1]. According to their
co-receptor usage or “tropism”, viruses are classified as
“R5” (interacting with CCR5) or “X4” (interacting with
CXCR4). Additionally, there are dual-tropic “R5X4”
strains that use both co-receptors for cell entry. Trop-
ism is mainly determined by the sequence of the vari-
able loop 3 (V3) of gp120. In initial infection, R5 viruses
dominate the viral quasi-species [2]. As the disease pro-
gresses, about 50% of the patients develop X4 virus [3].
CCR5 blocking drugs, such as Maraviroc or Vicriviroc
[4,5] are ineffective against X4 virus, and thus it is advi-
sable to test tropism prior to treatment with these
drugs. The current state-of-the-art is testing by phenoty-
pic assays such as Trofile® (Monogram Biosciences, CA)
[6] or enhanced sensitivity Trofile® assay (ESTA) [7].
However, their restriction to specialized laboratories,
high cost and long turn-around are limiting availability.
Moreover, phenotypic assays have been reported to fail
in delivering any result in more than 15% of the
cases [8]. An alternative for routine diagnostics is geno-
typic testing: the genomic sequence of V3 from a patient
is interpreted using computational models that relate V3
sequence and tropism. These models are typically
derived by machine learning methods from a training
set of V3 sequences and corresponding phenotypic test
results [9-14]. Genotypic predictions can be made avail-
able via the Internet, and they are fast and cheap. Fail-
ure rates have been estimated to be around 7.5% [8]. In
clinical settings with tropism predictions based on single
sequences from bulk sequencing, genotypic methods
tend to perform less well [15], which is mostly attribu-
ted to low detection rates of X4 minorities by bulk
sequencing [16]. Genotypic testing based on so-called
“next generation sequencing” or “deep sequencing”
methods may not suffer from this limitation [17] as they
provide detailed data for the whole viral quasi-species.
In fact, Vandenbroucke et al. [18] have demonstrated
that a combination of deep sequencing of V3 with a
genotype interpretation algorithm [11,19] can be used
for determination of tropism even in cases where phe-
notypic testing fails. In their study, the error rate of pre-
diction methods was a limiting factor.
Recently, we have devised a two-level machine learn-
ing approach (T-CUP) [14] for the prediction of HIV-1
co-receptor usage from V3 sequences. At the first level,
two independent predictions are made, based on the
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V3 loop, respectively. The predictions are then com-
bined, and a final decision is reached. The method is
accurate, provides predictions for all subtypes and is
robust with respect to insertions and deletions. In this
study, we applied T-CUP to deep sequencing data from
Tsibris et al. [21], compared the predictions with results
of phenotypic assays, and analyzed features of the viral
quasi-species that could indicate tropism switches. Tsi-
bris et al. had generated deep sequencing data for four
patients at three time points during treatment with
Vicriviroc, and concurrently had measured phenotypic
tropism with the standard Trofile® assay. These assays
had shown R5 virus at treatment start (Week 0 in Figure
1 and 2) for all patients. The common feature of all four
patients was failure of Vicriviroc therapy.
We extracted V3 sequences in the viral quasi-species
from the data published by Tsibris et al.b ya l i g n m e n t
to reference HXB2 V3 using Smith-Waterman local
alignment [22] and translation into the corresponding
amino acid sequence (Table 1). The tropism for every
sequence in the quasi-species of each patient was pre-
dicted using T-CUP. The fraction of predicted X4 virus
(i.e. number of predicted X4 tropic sequences divided by
total number of sequences) in a quasi-species was com-
pared with the outcome of the corresponding Trofile®
test. Figure 1 shows that there is a perfect agreement of
the two Trofile® classes R5 and DM (dual/mixed) with
predicted X4 tropic fractions of below and above 0.1,
respectively. This agreement holds for all four patients
and all time points, and is concordant with reports of
reliable detection of X4 minorities in test mixtures by
t h es t a n d a r dT r o f i l e ®a s s a ya tc o n c e n t r a t i o n sd o w nt o
5-10% [6]. The phenotypic tropism assay has dichoto-
mous output (either R5 or DM), while the T-CUP analy-
sis of deep sequencing data generates a practically
continuous (fraction of X4 tropic virus in quasi-species
in units of 1/(number of reads)). The latter allows for a
more detailed characterization of the dynamics of the
quasi-species with respect to tropism. It should be
noted that the density of sampling points along the time
axis in the Tsibris et al. dataset is too small for an accu-
rate modeling of the tropism dynamics. However, the
slopes of the lines in Figure 1 illustrate the principle.
For instance, in the computational analysis of the quasi-
species in Subject 07 we see an increase of the X4 frac-
tion from week 0 over week 12 to week 19. From the
slope between week 0 and week 12 we could extrapolate
that shortly after week 12 a switch from R5 to DM
should occur in the phenotypic assay. In fact, the phe-
notype data shows that the tropism switches between
weeks 12 and 19 from R5 to DM. In the same way we
would expect that the virus in Subject 18 remains DM
tropic, and in Subject 47 R5 tropic. Subject 19 is a parti-
cularly interesting case with an early switch from R5 to
DM, accompanied by a steep increase in the X4 fraction
according to T-CUP to 0.5 at week 2. Then the X4 frac-
tion drops to slightly above 0.1 at week 17. From this
development we could extrapolate a reversion from DM
to R5 shortly after week 17 (dashed blue line in Figure
1), as observed by Tsibris et al. [21].
We next exploited the property of T-CUP to provide
in the first level two independent tropism predictions
based on physical properties (electrostatics and hydropa-
thy) of V3. The corresponding probabilities span a plane
(“probabilities plane”) in which every V3 sequence is
represented by a point and the quasi-species by a cloud
of such points. Figure 2 shows this plane for all twelve
datasets from Ref. [21] with the points colored accord-
ing to frequency of the respective sequence in the deep
sequencing data.
The dynamics of the quasi-species in the probabilities
plane has several remarkable features. First, all
sequences in week 0 cluster in the lower left corner of
the plane as is expected for a quasi-species that is R5
tropic. Second, the movement of the clouds indicates
the dynamics of tropism. For Subjects 07 and 18 the
clouds move towards the upper right, i.e. to more X4
tropism. For Subject 19 this movement is also seen for
the first two time points but then reverts again to the
lower left, i.e. to more R5 tropism. Subject 47 shows no
marked movement to the upper right but remains loca-
lized in the lower left, in agreement with a quasi-species
that remains R5 tropic. Third, for the patients 07, 18,
and 19 where a co-receptor switch had been observed,
Figure 1 Development of fraction of X4 viruses. Development of
predicted fraction of X4-using viruses during Vicriviroc treatment for
four patients (right vertical axes, orange squares), and the
contribution of that fraction to the absolute viral load (left vertical
axes, black circles). Labels “R5” (R5-using) and “DM"(dual/mixed or
X4-using) are Trofile® results at the given times. The dotted line
marks the 10% detection rate of standard Trofile® assay. Naming
was adopted from [21].
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Page 2 of 5Figure 2 Development of quasi-species. Development of HIV-1 quasi-species in patients. Every dot represents a combination of two tropism
predictions for the same V3 sequence: one prediction based on electrostatic potential (ESP), the other on hydropathy. Colors code the number
of reads (color legend in top line). Dashed lines distinguish between R5 and X4 classes of the first level predictors. Cutoffs were chosen at 90%
specificity in the training set. Arrows mark X4 seed strains responsible for tropism switch.
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Page 3 of 5there is only one clearly dominating X4 strain in the
probabilities plane, and this strain is already present at
therapy start with considerable frequency (bright spots
with green arrows). This “X4 seed strain” is specific for
each of the patients - the seed strains for different
patients are clearly located in different regions of the
probabilities plane. Additionally, the X4 seed strain is
accompanied from the beginning by a growing halo of
local minor variants. Note that Subject 47 who remains
R5 tropic throughout all time points does not have such
a cluster.
We interpret the seed strain with its halo as a variant
that has established itself in the quasi-species even at
w e e k0s ot h a ti tc a ng e n e r a te a considerable number
of copies and also generates variant offspring. This
interpretation is supported by the high homology of
the sequences in the cluster (Figure 3). Using the sta-
tistical properties of this cluster in the probability
plane (strong seed strain, halo of neighbor strains), it
may become possible to predict af u t u r ec o - r e c e p t o r
switch and therapy failure many weeks earlier than the
switch of tropism becomes manifest in a phenotypic
test. For such an early detection of a later switch of
tropism, the resolution of deep sequencing and the
accuracy of the prediction method is critical. For all
three subjects where a switch occurs, the X4 seed
strain initially accounts for 0.5% to 1% of the quasi-
species (Table 2). The following progression towards
X4 tropism is almost exclusively due to the expansion
of these seed strains. For the three patients with a
tropism switch a linear correlation of development of
the total X4 fraction over time with the development
of the fraction of the seed strain over time yields R
2 =
0.98 (p =7 . 7·1 0
-10).
Although the high cost of deep sequencing will prob-
ably prevent its use in routine diagnostics in the near
future, the combination of this powerful method with
accurate predictions could be applied when phenotype
testing fails and to study evolution of viral quasi-species
under selective pressure, and thus contribute to the
development of sustainably effective treatments.
Table 1 Unique V3 sequences
Patient time 1 time 2 time 3
07 174 112 86
18 240 112 41
19 148 134 104
47 126 84 78
Number of unique sequences used in the analysis for each patient and each
of the three sample times. Based on the data provided by Tsibris et al., a cut-
off of a minimum of 4 reads per sequence was applied to limit the number of
spurious sequences.
Figure 3 Homology to X4 seed strain. For each sequence si the
Euclidean distance to the seed sequence sseed in the probabilities
plane (Figure 2) is given on the vertical axis, while the horizontal
axis shows the “alignment distance” to the seed sequence given by
(1 – A(si, sseed))/(A(sseed, sseed)) with sequence alignment score A
based on Needleman-Wunsch alignment [23] with scoring matrix
BLOSUM62 [24]. The lower the alignment distance, the higher the
homology to the seed strain. Sequences predicted as “X4” are
orange, those predicted “R5” cyan. The seed sequence is the red
point in lower left corner. The figure shows that sequences close to
the seed strain in Figure 2 have also low alignment distance, i.e. are
close homologs.
Table 2 Development of X4 variants causing tropism switch
Patient Variant Fraction of population at
time 1 time 2 time 3
07 CTRPGNNTRRSIRIGPGQTFFAREDIIGDIRQAYC 0.01 0.07 0.73
18 CERPNNNTRQRLSIGPGRSFYTSRRIIGDVKKAHC 0.005 0.79 0.71
19 CTRPNNNTRKGIYLGPGRAFYTTDKIIGDIRQAHC 0.007 0.43 0.08
47 CTRPNNSTRKSINIGPGSAWYTTGDIIGDIRQAHC 0.0009 0.0 0.0
Development of the X4 seed strains in Subjects 07, 18, 19 with tropism switches and the largest initial X4 strain in patient 47 who does not show a tropism
switch. The three times are the sampling points along the “Time” axis in Figure 1.
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